MannKind Co. (NASDAQ:MNKD) Stock Holdings Increased by BNP Paribas Financial Markets

BNP Paribas Financial Markets boosted its position in MannKind Co. (NASDAQ:MNKD - Free Report) by 421.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 471,802 shares of the biopharmaceutical company's stock after buying an additional 381,298 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.17% of MannKind worth $2,968,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of MNKD. Price T Rowe Associates Inc. MD increased its holdings in shares of MannKind by 5.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 172,054 shares of the biopharmaceutical company's stock valued at $780,000 after acquiring an additional 9,410 shares during the last quarter. 180 Wealth Advisors LLC raised its holdings in shares of MannKind by 4.7% during the second quarter. 180 Wealth Advisors LLC now owns 2,034,134 shares of the biopharmaceutical company's stock worth $11,411,000 after purchasing an additional 91,924 shares during the period. Brookstone Capital Management bought a new position in shares of MannKind in the 2nd quarter worth about $61,000. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of MannKind by 6.5% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 251,309 shares of the biopharmaceutical company's stock valued at $1,312,000 after buying an additional 15,423 shares during the period. Finally, Aaron Wealth Advisors LLC grew its position in shares of MannKind by 82.5% during the 2nd quarter. Aaron Wealth Advisors LLC now owns 176,998 shares of the biopharmaceutical company's stock valued at $924,000 after buying an additional 80,000 shares during the last quarter. Institutional investors and hedge funds own 49.55% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on MNKD shares. Leerink Partners initiated coverage on shares of MannKind in a report on Monday, September 9th. They issued an "outperform" rating and a $8.00 target price on the stock. Oppenheimer boosted their price objective on MannKind from $10.00 to $12.00 and gave the company an "outperform" rating in a research report on Wednesday, August 28th. Leerink Partnrs upgraded MannKind to a "strong-buy" rating in a research note on Monday, September 9th. Finally, StockNews.com upgraded MannKind from a "hold" rating to a "buy" rating in a research note on Friday, November 29th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, MannKind currently has an average rating of "Buy" and an average price target of $8.67.

Insider Buying and Selling

In other news, Director Steven B. Binder sold 67,539 shares of the stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $6.76, for a total value of $456,563.64. Following the completion of the transaction, the director now directly owns 1,075,026 shares in the company, valued at $7,267,175.76. This trade represents a 5.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Stuart A. Tross sold 55,000 shares of the business's stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $7.34, for a total value of $403,700.00. Following the sale, the insider now directly owns 967,191 shares in the company, valued at approximately $7,099,181.94. The trade was a 5.38 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 190,075 shares of company stock valued at $1,325,587 over the last 90 days. 3.00% of the stock is currently owned by company insiders.

MannKind Stock Performance

Shares of NASDAQ:MNKD traded up $0.07 on Friday, hitting $6.80. The company's stock had a trading volume of 1,899,315 shares, compared to its average volume of 2,644,753. The company has a market capitalization of $1.88 billion, a price-to-earnings ratio of 97.43 and a beta of 1.28. MannKind Co. has a 12 month low of $3.17 and a 12 month high of $7.63. The stock's 50-day moving average is $6.73 and its two-hundred day moving average is $5.89.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.